PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Salsali, Afshin
TI  - Empagliflozin Reduces BP in Hypertensive Type 2 Diabetics
DP  - 2014 Nov 01
TA  - MD Conference Express
PG  - 14--15
VI  - 14
IP  - 20
4099  - http://mdc.sagepub.com/content/14/20/14.short
4100  - http://mdc.sagepub.com/content/14/20/14.full
AB  - Prior 24-week Phase 3 clinical trials (randomized, double-blind) established the efficacy of empagliflozin (10 and 25 mg) in reducing systolic BP compared with placebo among patients with type 2 diabetes. This article presented findings of the 12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus [EMPA-REG BP; NCT01370005], a placebo-controlled Phase 3 trial (randomized, double-blind).